DESCRIPTION

*Mutation Research: Genetic Toxicology and Environmental Mutagenesis (MRGTEM)* publishes papers advancing knowledge in the field of genetic toxicology. Papers are welcomed in the following areas:

New developments in genotoxicity testing of chemical agents (e.g., in methodology of assay systems and interpretation of results). Alternatives to and refinement of the use of animals in genotoxicity testing. Nano-genotoxicology, the study of genotoxicity hazards and risks related to novel man-made nanomaterials. Studies of epigenetic changes in relation to genotoxic effects. The use of structure-activity relationships in predicting genotoxic effects. The isolation and chemical characterization of novel environmental mutagens. The measurement of genotoxic effects in human populations, when accompanied by quantitative measurements of environmental or occupational exposures. The application of novel technologies for assessing the hazard and risks associated with genotoxic substances (e.g., OMICS or other high-throughput approaches to genotoxicity testing). Telomere biology as an endpoint for examination of the effects of chemicals and other environmental exposures.

*MRGTEM* is now accepting submissions for a new section of the journal, "Current Topics in Genotoxicity Testing," that will be dedicated to the discussion of current issues relating to design, interpretation, and strategic use of genotoxicity tests. This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal’s aims, scope, and policies.


Other *Mutation Research* sections:
DNA Repair
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis (MR)
Mutation Research - Reviews (MRR)

AUDIENCE

Environmental Scientists, Occupational Health Researchers, Mutageneticists, Toxicologists

ABSTRACTING AND INDEXING

Chemical Abstracts
EMBiology
Web of Science
BIOSIS Citation Index
Current Contents - Life Sciences
Embase
PubMed/Medline
Pascal Francis
Reference Update
Scopus

EDITORIAL BOARD

Editors-in-Chief
P. Josephy, University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada
Siegfried Knasmueller, Medical University of Vienna Institute of Cancer Research, Wien, Austria

Associate Editor
Miroslav Mišík, Medical University of Vienna Institute of Cancer Research, Wien, Austria
DNA damage, Dietary mutagens, Comet, Micronuclei, Metabolically competent cell lines, Ecogenotoxicology, Plant bioassays

Regional Editors
Manoor Prakash Hande, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore
Telomeres and telomerase in ageing and cancer, DNA damage response and repair, toxicogenomics and environmental toxicology, radiation biology, biological response markers of exposure, experimental therapeutics, Genetic Toxicology
Yang Luan, Shanghai Jiao Tong University School of Medicine, Shanghai, China
DNA damage, Mutagenicity, Ultra-low frequencies mutation sequencing, Next generation sequencing

Founding Editor
Frits Sobels

Editorial Board
Dietrich Averbeck, Genotoxicology Signalisation and Experimental Radiotherapy, Orsay, France
Biology and chemistry of radiations, cell signalling in cancer
Gustavo Barcelos, Federal University of Sao Paulo, SAO PAULO, Brazil
Environmental toxicology, metals toxicology, epigenetics, organic toxicants, comet assay, micronucleus, epigenetics.
Claudia Bolognesi, Genoa, Italy
DNA Damage, oxidative stress biomarkers, cytotoxicity, cytogenetics, genotoxicity, cell cycle regulation, environmental mutagenesis, environmental carcinogens, mutagens
Markus Christmann, Johannes Gutenberg University Mainz, Mainz, Germany
DNA repair, genotoxic stress, transcriptional regulation of DNA repair genes
Andrew R. Collins, Fac. of Medicine,Dept. of Nutrition,University of Oslo, Oslo, Norway
Comet Assay, DNA damage and mutagenesis, nutrition and cancer, DNA repair in mammalian cells, human biomonitoring; molecular epidemiology
Juliana Da Silva, Lutheran University of Brazil Toxicological Genetics Laboratory, Canoas-RS, Brazil
Environmental Monitoring; DNA Damage; Mutagenesis; Genotoxicity; Comet Assay; Genetic Toxicology; Micronucleus Test; Occupational Exposure; Environmental Exposure

**Shareen H. Doak**, Swansea University, Swansea, United Kingdom
Genetic toxicology, nanotoxicology, DNA damage mechanisms, biomarkers, molecular biology of prostate cancer

**Maria Dusinska**, Norwegian Institute for Air Research, Kjeller, Norway
Cytotoxicity, DNA damage, mutagenicity, cancer biomarkers

**David A. Eastmond**, University of California Riverside, Riverside, California, United States of America
Mechanisms of toxicity and carcinogenesis of agricultural and environmental chemicals in humans and other mammals

**Patricia Escobar**, Merck Research Laboratories West Point, Lansdale, Pennsylvania, United States of America
Genetic Toxicology, Bacterial mutagenicity, DNA damage, Chromosomal Damage, genetox screening assay, mutagenic impurities, pharmaceutical industry

**Solangi Garcia**, Federal University of Rio Grande do Sul, PORTO ALEGRE, Brazil
Occupational and Environmental Toxicology; Nanotoxicology; Metals; Chemical agents

**Sabina Halappanavar**, Health Canada, Ottawa, Ontario, Canada
Gene Expression, immune response, nanotoxicology, DNA damage, toxicogenomics, carcinogens

**Shuiham Hamada**, Bozo Research Center Inc, Setagaya-Ku, Japan
Carcinogen; DNA damage; drug administration, gastrointestinal tract, liver micronucleus assay

**Cheryl Hobbs**, Inotiv, Research Triangle Park, North Carolina, United States of America
DNA damage, genotoxicity, error corrected next generation sequencing

**Klaus Holzmann**, Medical University of Vienna, Wien, Austria
Receptor signaling pathways, Telomere maintenance mechanisms, Targeted therapy, Reporter assays, In vitro cell models

**Yuko Ibuki**, University of Shizuoka, Shizuoka, Japan
Ultraviolet rays, Environmental chemicals, Epigenetics, Histone modifications, DNA damage, DNA repair

**Marina Isidori**, University of Campania Luigi Vanvitelli, Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Caserta, Italy
Acute and chronic aquatic toxicity, pharmaceuticals in the environment, environmental risk assessment, mutagenesis, genotoxicity, endocrine disruptors, cytotoxicity, food safety

**Gareth Jenkins**, Swansea University, Swansea, United Kingdom
DNA mutation, cancer biomarkers, oesophageal cancer, safety assessment, genetic toxicology

**Awadhesh N. Jha**, University of Plymouth, Plymouth, United Kingdom
Chemical and radiation mutagenesis, in vitro and molecular toxicology, nanotoxicology, environmental radioactivity, eco-genotoxicology, environmental monitoring, alternative methods in toxicology

**Bernd Kaina**, University Medical Center of the Johannes Gutenberg University Mainz Institute of Toxicology, Mainz, Germany
DNA repair, apoptosis

**Carina Ladeira**, Lisbon Polytechnic Institute Lisbon School of Health Technology, Lisboa, Portugal
Human biomonitoring, genotoxicity, genetic toxicology, histopathology, environmental and occupational health, toxicology, Chemical mixtures

**Mugimane Manjanatha**, National Center for Toxicological Research, Jefferson, Arkansas, United States of America
Transgenic mutation assays, assessment of chemicals and drugs

**Nan Mei**, National Center for Toxicological Research, Jefferson, Arkansas, United States of America
Toxicology, DNA Damage, Oxidative Stress, Genotoxicity, Hepatotoxicity, Cytotoxicity, Mutagenicity, Toxicogenomics, Gene Expression, Quantitative Analysis

**Mirita Milic**, Institute for Medical Research and Occupational Health, Zagreb, Croatia
Genetic toxicology, nanotoxicology, DNA polymorphisms, comet assay, micronucleus assay, chromosomal aberrations, ionizing radiation, occupational exposure, DNA damage, DNA repair

**Massimo Moretti**, University of Perugia, Perugia, Italy
Occupational exposure, antineoplastic drugs, genotoxicity

**Takeshi Morita**, National Institute of Technology and Evaluation, Shibuya-Ku, Japan
Genotoxicity, Testing, in silico, QSAR, Evaluation, Regulation, Risk assessment, Hazard identification, GHS classification

**Kristien Mortelmans**, SRI International, Menlo Park, California, United States of America
Screening of antimicrobial compounds

**Asao Noda**, Radiation Effects Research Foundation, Hiroshima, Japan
Radiation Biology, Somatic and germline mutation, DNA repair, Cellular aging

**Takehiko Nohmi**, National Institute of Health Sciences, Kawasaki, Japan

**AUTHOR INFORMATION PACK 14 Sep 2023**

www.elsevier.com/locate/gentox
Mutagenesis, DNA Repair, Genotoxicology

Shinji Oikawa, Mie University Graduate School of Medicine, Faculty of Medicine, Department of Environmental and Molecular Medicine, Tsu, Japan
Carcinogenesis, Mutagenesis, DNA damage, Oxidative stress

Emilio Rojas del Castillo, National Autonomous University of Mexico, Department of Medicine and Environmental Toxicology, Ciudad de México, Mexico
DNA damage and repair, Gene expression, Epigenetic effects, cell transformation, environmental exposure, human exposed populations

José Rueff, Nova University of Lisbon, Lisboa, Portugal
DNA repair, genetic susceptibility, mismatch repair

Stephanie Smith-Roe, National Toxicology Program, Research Triangle Park, North Carolina, United States of America
Genetic toxicology, DNA damage, DNA repair, mutagenesis, cell cycle checkpoints, high throughput screening, botanical dietary supplements

Helga Stopper, Julius Maximilians University Wurzburg, Department of Toxicology, Wurzburg, Germany
Genetic toxicology, Mechanisms of action of carcinogenic agents, Electromagnetic fields and genomic damage, Genomic damage through endogenous hormones

Takeji Takamura-Enya, Kanagawa Institute of Technology Graduate School of Engineering Course of Applied Chemistry and Bioscience, Atsugi, Japan
fluorescence microscopy, water quality, boron, copper

Jan Topinka, Czech Academy of Sciences, Praha, Czechia
Toxic effects of engineered nanoparticles, combustion generated particles, molecular epidemiology

Yukari Totsuka, National Cancer Center Research Institute Cancer Development and Progression Group Division of Carcinogenesis and Prevention, Tokyo, Japan
Carcinogenesis

Mahara Valverde, National Autonomous University of Mexico, Department of Medicine and Environmental Toxicology, Ciudad de México, Mexico
Transformative effects of metals, DNA repair mechanisms, oxidative stress, Adipogenesis, Comet assay, DNA damage, DNA damage responde (DDR), Carcinogenesis

Marie Vasquez, Helix3 Inc, Morrisville, North Carolina, United States of America
 Comet assay, Genetic toxicology, DNA damage and repair, DNA reactivity, cytotoxicity, safety testing

Perumal Venkatachalam, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
51);”>Radiation biodosimetry, biological effects of low-dose ionizing radiation (Bystander response, Genomic instability, Adaptive response), biomarkers of radiation exposure and radiation response (Chromosome aberrations, micronucleus, translocations, gamma-H2AX assay), clinical cytogenetics.

Vijayalaxmi, The University of Texas Health Science Center at San Antonio, Department of Radiology, San Antonio, Texas, United States of America

Kristine Witt, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America
Bacterial mutation, Comet assay, Chromosomal damage, Micronucleus test, Pig-a assay,, Genetic toxicology, Pig-a assay

Lijun Wu, Anhui University Institute of Physical Science and Information Technology, Hefei, China
Radiobiology

Bojana Žegura, National Institute of Biology, Ljubljana, Slovenia
genotoxicity, mutagenicity, toxicogenomics, natural toxins, anti-mutagens, in vitro 3D cultures
GUIDE FOR AUTHORS

INTRODUCTION

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* publishes papers advancing knowledge in the field of genetic toxicology. Papers are welcomed in the following areas:

New developments in genotoxicity testing of chemical agents (e.g. improvements in methodology of assay systems and interpretation of results). Alternatives to and refinement of the use of animals in genotoxicity testing. Nano-genotoxicology, the study of genotoxicity hazards and risks related to novel man-made nanomaterials. Studies of epigenetic changes in relation to genotoxic effects. The use of structure-activity relationships in predicting genotoxic effects. The isolation and chemical characterization of novel environmental mutagens. The measurement of genotoxic effects in human populations, when accompanied by quantitative measurements of environmental or occupational exposures. The application of novel technologies for assessing the hazard and risks associated with genotoxic substances (e.g. OMICS or other high-throughput approaches to genotoxicity testing). Telomere biology as an endpoint for examination of the effects of chemicals and other environmental exposures.

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* is now accepting submissions for a new section of the journal that will be dedicated to the discussion of current issues relating to design, interpretation and strategic use of genotoxicity tests (*Current Topics in Genotoxicity Testing*). This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal’s aims, scope, and policies.

**Types of Paper**

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* publishes the following types of article: (I) Research papers- papers reporting results of original, fundamental research. (II) Short communications of up to 5 printed pages. (III) Rapids - are accelerated publications - research papers identified by the Editor as being of significant quality and thereby qualifying for rapid reviewing, and publication within 8-10 weeks of acceptance. (IV) Current issues are generally short, 1-2 page comments on a topical theme, and are published within 10 weeks of acceptance. (V) Volunteered and invited Mini-reviews of less than 10 printed pages, using references generally no later than 2 years old. The journal accepts Letters to the Editor.

Please note that Full-length reviews comprehensively covering and critically analysing a topic are published in *Mutation Research Reviews*. Also published in the Reviews section are invited papers in the series *Reflections in Mutation Research*, in which research and techniques that have played an important part in the development of the field of mutation research are revisited and their significance discussed. Special issues, comprising multiple original and/or review articles written from a particular viewpoint, on a central theme, are published on a regular basis in the appropriate section of Mutation Research by topic or article type.

**Current Topics in Genotoxicity Testing**

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* is now accepting submissions for a new section of the journal that will be dedicated to the discussion of current issues relating to design, interpretation and strategic use of genotoxicity tests (*Current Topics in Genotoxicity Testing*). This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal’s aims, scope, and policies.

Any submissions that report the results of studies on extracts or complex mixtures (e.g., solvent extracts of herbal preparations; soil, air, or water samples) will receive preliminary review by an Editor. Unless such manuscripts offer significant new insight, such as the chemical identification of previously unknown mutagens or anti-mutagens, they will be returned to the authors without being sent for further review. For further clarification of this journal policy please refer to the *Editorial* published in Mutation Research 391 (1997) 1.
It is the policy of the Editors to conduct a preliminary review of each submitted manuscript that reports the results of molecular epidemiology studies. (i) As with any studies involving human subjects, approval by an appropriately constituted ethics review board and informed consent by participants are required. (ii) Authors are advised to collaborate with qualified epidemiologists with respect to study design and interpretation. (iii) In studies of the potential genotoxic effects of exposure to environmental agents, it is strongly recommended that quantitative evidence of exposure (such as analysis of personal monitoring devices or measurement of urinary biomarkers, for example) be obtained. Manuscripts which do not conform to these requirements will be returned to the authors without being sent for further review.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council's Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of interest statement using https://www.elsevier.com/declaration-of-competing-interests and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose: ‘Declarations of interest: none’ in the template. More information.

Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.
Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

**Statement**: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Reporting sex- and gender-based analyses**

**Reporting guidance**
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what
definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

**Elsevier supports responsible sharing**
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

**Funding body agreements and policies**
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit https://www.elsevier.com/fundingbodies.

**Open access**
Please visit our Open Access page for more information.

**Elsevier Researcher Academy**
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Referees**
This journal requires authors to submit at least 4 referees, including their name, institution, e-mail and expertise relevant to the manuscript. The criteria to select referees are as follows: at least 2 suggestions must include members of the Editorial Board must not be from the same institution as the authors must not have co-authored a paper with any of the authors in the past 3 years no more than 1 suggestion should be from the same country as the authors, reviewers must be from a variety of countries and continents

The Editors reserve the right to use these or other reviewers.

**Free access to scientific publications for public institutions in developing countries:**
The Health InterNetwork Access to Research Initiative (HINARI) is an initiative to provide free or nearly free access to the major journals in biomedical and related social sciences, to public institutions in developing countries. Starting in January 2002 with over 2000 journals from Elsevier and other leading biomedical publishers, HINARI is part of the Health InterNetwork, which was introduced by the United Nations' Secretary General Kofi Annan at the UN Millennium Summit in the year 2000.
For further information and registration, please check the HINARI site: http://www.who.int/hinari/en/

**PREPARATION**

**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**Peer review**
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

**Use of word processing software**
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - numbered sections**
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

**Introduction**
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**
Results should be clear and concise.

**Discussion**
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

**Conclusions**
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

**Appendices**
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors’ affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author’s name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself. **The abstract should be up to 300 words of size.**

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

**Keywords**

Authors should supply 5 or 6 keywords separated by semicolons [e.g. Cytochrome P450; oxidoreductase; Gene knockout; DNA adducts; Bacterial mutagenicity testing; Double-strand break]. Each individual keyword may be up to 256 characters in length. Please take the time to choose your keywords carefully as they increase the discoverability of your article via search engines. They should not be words from the title or the abstract specifically because that would not improve the discoverability.

**Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) and in the printed version (unless you specify otherwise). Please indicate your preference for color: in print and on the Web, or on the Web only. For further information on the preparation of electronic artwork, please see https://www.elsevier.com/artworkinstructions.

Please note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
**Data references**

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Preprint references**

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

**References in a special issue**

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

**Reference management software**

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

**Reference formatting**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume and issue/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

**Reference style**

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

**Examples:**

Reference to a journal publication:

Reference to a journal publication with an article number:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a website:

Reference to a dataset:
Reference to software:

**Journal abbreviations source**

Journal names should be abbreviated according to the List of Title Word Abbreviations.

**Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**

This journal requires and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. When sharing data in one of these ways, you are expected to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

Submission Checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Phone numbers
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web and in print, or to be reproduced in color on the Web and in black-and-white in print. There are no color charges for Web and/or print reproduction
• If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at https://service.elsevier.com.

AFTER ACCEPTANCE
Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is
accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com